VELCADE,Rituximab,Cyclophosphamide and Decadron

Stopped early · Phase 2

Conditions studied: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

In brief

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

Key facts

Study ID

NCT00413959

Run by

Oncology Specialists, S.C.

People needed

12

Starts

2006-08-01

Expected to finish

2011-01-01

Last updated by the study team

2018-09-19

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Small Lymphocytic Lymphoma
• Follicular Cell Lymphoma (grades I and II)
• Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant
• Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia
• Marginal Zone Lymphoma
• MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.
• Adequate bone marrow function, renal function, and hepatic function as outlined in details below.
• ECOG performance status of 0, 1, or 2
• Able to read, understand, and sign an IRB approved informed consent

You may not qualify if…

• Known HIV positive status
• Known CNS involvement
• Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.

Where it is running

• Onocology Specialists, S.C — Niles, Illinois, United States
• Oncology Specialists, S.C — Park Ridge, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.